All In Biotech

Free tool

FAERS Monitor: Kazano

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203414 or its brand name (Kazano, Alogliptin Benzoate, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

140

Serious

62

44% of reports

Hospitalization

27

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea17
  • nausea14
  • drug ineffective12
  • blood pressure increased10
  • dyspnoea10
  • heart rate increased8
  • hypertension8
  • pneumonia8
  • blood glucose increased7
  • chest pain7
  • anxiety6
  • back pain6
  • disease recurrence6
  • malaise6
  • rash6

Reports by year received

View as table
YearReports
20133
201432
201521
201621
20177
20185
20197
202010
20211
202212
20234
20249
20255
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease recurrenceSignal618.98.785
heart rate increasedSignal812.16.271
blood pressure increasedSignal109.85.471
chest painSignal75.72.823
hypertensionSignal85.72.927
blood glucose increasedSignal75.62.722
diarrhoeaSignal174.02.536
back painSignal63.91.810
pneumoniaSignal83.71.913
anxietySignal63.21.47
nauseaSignal142.71.613
dyspnoeaSignal102.71.59
rash62.10.92
malaise62.10.92
drug ineffective121.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.